Affordability versus innovation: Is compulsory licensing the solution?

Area of Science:

• Health Policy
• Intellectual Property Law
• Global Health

Background:

• Despite scientific advancements, significant healthcare access disparities persist globally.
• Pharmaceutical patents, intended to incentivize innovation, create barriers to accessing essential medicines, particularly in low- and middle-income countries.
• Existing health financing mechanisms in poorer nations are often inadequate to cover medicine costs.

Purpose of the Study:

• To analyze the utilization of compulsory licensing as a mechanism to overcome legal and political barriers to medicine access.
• To evaluate policy approaches for granting compulsory licenses across diverse countries.
• To identify best practices for evidence-based policymaking concerning pharmaceutical patents and global health equity.

Main Methods:

• Cross-country comparative analysis of patent frameworks.
• Examination of compulsory licensing cases in selected developed and developing countries.
• Review of international trade agreements influencing patent law extension.

Main Results:

• Evidence supporting the justification for patent laws incentivizing R&D is limited.
• Compulsory licensing has been employed as a tool to address medicine access challenges.
• International trade agreements have driven the extension of patent laws globally.

Conclusions:

• Compulsory licensing offers a viable strategy to mitigate barriers to essential medicine access.
• Policy approaches to compulsory licensing vary, necessitating the identification of best practices.
• Addressing the drug gap requires international cooperation on pharmaceutical patent policies to achieve sustainable development goals.